List view / Grid view
6 June 2016 | By Victoria White, Digital Content Producer
Data were presented from two early-phase trials evaluating Lilly's Alimta and Cyramza in combination with Merck's Keytruda in patients with NSCLC...
6 June 2016 | By Victoria White, Digital Content Producer
New data for Bristol-Myers Squibb’s Opdivo has been presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)...
6 June 2016 | By Victoria White, Digital Content Producer
Daratumumab, in combination with bortezomib and dexamethasone, demonstrated a 61% reduction in the risk of disease progression or death...
6 June 2016 | By Victoria White, Digital Content Producer
We recently caught up with Dr Jörg Barth, Boehringer Ingelheim, to find out more about the company’s oncology pipeline and presence at ASCO....
3 June 2016 | By Victoria White, Digital Content Producer
Neuroblastoma tumours shrank in 80% of young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody...
1 June 2016 | By Victoria White, Digital Content Producer
New data strengthen the body of research into Opdivo, hailing it as the new standard of care in recurrent metastatic renal cell carcinoma (mRCC)...
27 May 2016 | By Victoria White, Digital Content Producer
Scientists are able to identify patients with stomach cancer who are most likely to respond to AZD4547 by measuring copies of the FGFR2 gene in the bloodstream...
5 May 2016 | By Victoria White, Digital Content Producer
Eribulin is approved for those patients who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease...
4 May 2016 | By Osuntokun Oludare Temitope and Ogunleye Adewale Joseph, Adekunle Ajasin University
The aetiology of tumours is attributed to changes in many internal (molecular) factors, most of which include mutations in several regulatory mechanisms and the loss of cell differentiation. Human isoforms of the p53 protein play a key role in maintaining genetic stability, functioning as active tumour suppressors. However, a mutation…
28 April 2016 | By Jon Pender, VP Government Affairs, GSK
Jon Pender, GSK, discusses how a flexible and thoughtful approach to IP can help get medicines to the poorest and hardest-to-reach patients around the world...
19 April 2016 | By Victoria White, Digital Content Producer
The total immuno-oncology market will be worth approximately $14 billion by 2019, rising to $34 billion by 2024, according to GlobalData...
31 March 2016 | By Victoria White
Children with cancer will be offered testing for genetic mutations in their tumours as part of an initiative to personalise children’s cancer treatment...
16 March 2016 | By Victoria White
Vx-001 is a therapeutic cancer vaccine based on proprietary antigens known as optimised cryptic tumour peptides...
15 March 2016 | By Victoria White
According to GlobalData analysts, hopes for improved therapies for glioblastoma have turned to Opdivo and drugs combining peptide vaccines with immuno-oncology products...
14 March 2016 | By Black Swan Analysis
Two big things struck me as interesting during an Innovations in Oncology Conference in Edinburgh this month...
